Clinical Trials
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
21CTP.HN01
Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis
Status Notes
Activation - Effective 09/15/2025
SWOG Clinical Trials Partinerships
https://www.swogctp.org/trials/21ctphn01/
SWOG Clinical Trials Partinerships
https://www.swogctp.org/trials/21ctphn01/
Research Committee(s)
SWOG CTP
Head and Neck Cancer
Activated
09-15-2025
ClinicalTrials.gov Registry Number
07062354
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Status Notes
Active as of 9/4/2025.
Research Committee(s)
Genitourinary Cancer
Activated
09-04-2025
ClinicalTrials.gov Registry Number
07061964
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2417CD
A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
Status Notes
This study is open to accrual, effective 8/4/2025 at 12:00 p.m. PT.
Research Committee(s)
Cancer Care Delivery
Gastrointestinal Cancer
Activated
08-04-2025
ClinicalTrials.gov Registry Number
NCT 07018869
Open
Phase
Accrual
11%
SWOG Clinical Trial Number
S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Status Notes
Effective April 28, 2025 at 12:00 p.m. Pacific Time, sub-study S1800E will be open to accrual. This is a potential FDA Registration Trial. Additional site requirements include:
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
Research Committee(s)
LungMAP
Activated
04-28-2025
ClinicalTrials.gov Registry Number
NCT06616584
Open
Phase
Accrual
8%
SWOG Clinical Trial Number
MM1OA-S03
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
Research Committee(s)
myeloMATCH
Leukemia
Activated
04-01-2025
ClinicalTrials.gov Registry Number
NCT06672146
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Status Notes
Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03-14-2025
ClinicalTrials.gov Registry Number
06498635
Open
Phase
Accrual
19%
SWOG Clinical Trial Number
S2408
A Randomized Phase III Blinded Trial of lanreotide for the Prevention of Postoperative Pancreatic Fistula
Research Committee(s)
Palliative and End of Life Care Committee
Gastrointestinal Cancer
Activated
02-14-2025
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S1900J
A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
09-27-2024
ClinicalTrials.gov Registry Number
NCT06116682
Open
Phase
Accrual
7%
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Status Notes
S2312 active as of 9/3/2024.
Research Committee(s)
Genitourinary Cancer
Activated
09-03-2024
ClinicalTrials.gov Registry Number
06470243
Open
Phase
Accrual
37%
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Status Notes
S2308 will open to accrual 08/01/2024, effective 3:00 p.m. EST
Research Committee(s)
Lymphoma
Activated
08-01-2024
ClinicalTrials.gov Registry Number
06337318
Open
Phase
SWOG Clinical Trial Number
MYELOMATCH
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials
Research Committee(s)
myeloMATCH
Leukemia
Activated
05-16-2024
ClinicalTrials.gov Registry Number
NCT05564390
Open
Phase
Accrual
16%
SWOG Clinical Trial Number
MM1YA-S01
A Randomized Phase II Study Comparing Cytarabine +Daunurubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
Research Committee(s)
myeloMATCH
Leukemia
Activated
05-16-2024
ClinicalTrials.gov Registry Number
NCT05554406
Open
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05-06-2024
ClinicalTrials.gov Registry Number
06203600
Open
Phase
Accrual
29%
SWOG Clinical Trial Number
S1900K
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
12-18-2023
ClinicalTrials.gov Registry Number
NCT06031688
Open
Phase
Accrual
9%
SWOG Clinical Trial Number
S2213
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Status Notes
S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Myeloma
Activated
12-01-2023
ClinicalTrials.gov Registry Number
06022939
Open
Phase
Accrual
29%
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Status Notes
This study is open to patient accrual effective 10/30/23.
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10-30-2023
ClinicalTrials.gov Registry Number
06058377
Open
Phase
Accrual
14%
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Status Notes
Active as of 08/14/2023, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
08-14-2023
ClinicalTrials.gov Registry Number
NCT05806515
Open
Phase
Accrual
43%
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Status Notes
This study is active in SWOG as of July 21, 2023.
Research Committee(s)
Breast Cancer
Activated
07-21-2023
ClinicalTrials.gov Registry Number
NCT05929768
Open
Phase
Accrual
14%
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Status Notes
Effective October 29th, 2024, at 12:00 p.m. Pacific, Arm 3 will temporarily close to accrual.
Effective June 13, 2024, at 12:00 a.m. Pacific, Arm 1 will temporarily close to accrual.
Effective June 13, 2024, at 12:00 a.m. Pacific, Arm 1 will temporarily close to accrual.
Research Committee(s)
Lymphoma
Activated
06-30-2023
ClinicalTrials.gov Registry Number
05890352
Open
Phase
Accrual
21%
SWOG Clinical Trial Number
S2209
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Status Notes
S2209 is open to patient accrual May 30, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Myeloma
Activated
05-30-2023
ClinicalTrials.gov Registry Number
05561387